Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Carcinoma, Non-Small-Cell Lung 1

Interventions

lutetium Lu 177 dotatate 12Specimen Handling 6Magnetic Resonance Spectroscopy 6cabozantinib 5Everolimus 5pembrolizumab 4Nivolumab 4olaparib 3lenvatinib 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2tivozanib 1surufatinib 1repotrectinib 1peposertib 1pazopanib 1entrectinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × surufatinib × 90 days × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡